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The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in
head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism
of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased
levels of the ERBB3/ERBB4 ligand heregulin.The advent of targeted biologic agents
has revolutionized treatment for many
types of cancer by focusing therapy
on specific aberrant signaling pathway
components. One such target, the epi-
dermal growth factor receptor (EGFR, or
ERBB1), is overexpressed in many can-
cers, including colorectal (CRC), head
and neck, bladder, and nonsmall cell
lung cancer (NSCLC), and overexpression
correlates with poor outcomes. Cetuxi-
mab, a monoclonal antibody directed
against the ligand-binding domain of the
EGFR, can inhibit cell growth and survival
in a number of malignancies, and it is
currently approved by the FDA for the
treatment of head and neck squamous
cell carcinoma and metastatic CRC.
Unfortunately, treatment response to
cetuximab has not been uniform because
a subset of patients shows poor response
up front, whereas others develop resis-
tance after initial benefit. Well-established
causes of de novo cetuximab resistance
include activating mutations in KRAS
codons 12 and 13 and BRAF, with the
impact of PI3KCA and NRAS mutationsless clear. A recent study by Yonesaka
et al. (2011) has identified a new mecha-
nism of de novo and acquired resistance
to cetuximab therapy via increased
signaling through ERBB2, a member of
the ErbB family of receptor tyrosine
kinases. Importantly, they demonstrate
that either amplification of ERBB2 or
increased levels of the ERBB3/ERBB4
ligand heregulin are present in patients
with CRC that exhibited de novo or
acquired cetuximab resistance.
Resistance to EGFR-targeted therapy
is typically mediated though alternate
means of extracellular signal-regulated
kinase 1/2 (ERK1/2) activation that
bypass EGFR either via alternative recep-
tors at the plasma membrane or constitu-
tively active downstream components.
By generating cetuximab-resistant cell
lines, Yonesaka et al. first identified mul-
tiple clones that exhibited less effective
suppression of ERK1/2 phosphorylation
in the presence of cetuximab. Further
analysis of these clones revealed amplifi-
cation of ERBB2 with corresponding
increases in total and phospho-ERBB2levels. Subsequent depletion of ERBB2
in the resistant clones restored sensitivity
to cetuximab, confirming the importance
of ERBB2 in the resistant phenotype.
In addition to ERBB2 amplification,
Yonesaka et al. uncovered a subset of
cetuximab-resistant clones where ac-
quired resistance was mediated instead
by increased levels of heregulin, a ligand
that binds ERBB3 and ERBB4. These
elevated levels of heregulin resulted in
increased association between ERBB2
and ERBB3 and subsequent activation
of downstream targets. Interestingly,
this is analogous to hormone-refractory
breast cancer where heregulin induces
estrogen independence and metastasis
in part through an increase in ERK1/2
and suspected ERBB activity (Atlas
et al., 2003). The expression levels of
other ERBB ligands were not addressed
by Yonesaka et al., and so their potential
contribution to ERBB2-mediated resis-
tance in this experimental system is
unclear. The role, if any, of these other
ligands would be interesting because
upregulation of some ligands may also, October 18, 2011 ª2011 Elsevier Inc. 423
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Figure 1. Mechanisms of Resistance to EGFR-Targeted Therapy
(A) Seven different mammalian EGFR ligands bind and activate EGFR, initiating complex signaling
cascades that include activation of ERK1/2 (Proliferation) and Akt (Survival).
(B) In solid tumors, monoclonal antibodies that block EGFR ligand binding (e.g., cetuximab) or EGFR-
selective tyrosine kinase inhibitors (TKIs) prevent activation of downstream-signaling components.
De novo or acquired resistance to cetuximab may develop through ERBB2 amplification and increased
levels of the ERBB3/ERBB4 ligand heregulin (Yonesaka et al., 2011), or to TKIs throughMET amplification
(Engelman et al., 2007)—in both instances, ERBB3 is activated. Additional mechanisms of resistance
to EGFR-targeted therapies may exist de novo (mutant KRAS, BRAF, EGFRvIII) or be selected for
(EGFR T790M).
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cetuximab resistance), whereas upregu-
lation of other ligands (i.e., EREG and
AREG) in the pretreatment setting has
been shown to correlate instead with
sensitivity to cetuximab (Bertotti et al.,
2011; Khambata-Ford et al., 2007).
As a complement to these in vitro
results, Yonesaka and colleagues were
able to demonstrate that alterations in
ERBB2 signaling correlate with acquired
resistance to cetuximab in a clinical
setting. Although the number of analyzed
patient samples was limited, amplification
of ERBB2 and increased heregulin levels
were observed after patients became
nonresponsive to cetuximab therapy.
Yonesaka et al. also presented more
comprehensive clinical data indicating
that ERBB2 amplification and elevated
heregulin play a role in de novo resistance
as well. In patients with CRC treated
with cetuximab, levels of serum heregulin
protein and tumor heregulin mRNA,
though widely variable, were significantly
higher in patients with stable or pro-
gressive disease. These higher levels424 Cancer Cell 20, October 18, 2011 ª2011of heregulin appeared to correlate with
reduced progression-free and overall
survival. The presence of ERBB2 amplifi-
cation in a larger patient cohort also
correlated with worse overall survival.
Of the 233 patients with CRC examined,
approximately 5.5% showed amplifica-
tion of ERBB2, which is analogous to
the 5.2% of metastatic CRC and 3.6%
of head and neck squamous cell carci-
nomas with ERBB2 amplification found
in other cohorts (Personeni et al., 2008;
Stransky et al., 2011). Importantly, ele-
vated heregulin or ERBB2 amplification
resulted in worse survival among patients
with wild-type KRAS when examined
independently. Overall, the specificity
of these correlations is somewhat un-
certain because we do not yet know if
ERBB2 amplification or elevated heregu-
lin levels are poor prognostic factors
independent of cetuximab therapy.
Furthermore, data on progression-free
and overall survival should be interpreted
with caution because these are retro-
spective analyses on a heterogeneous
group of patients.Elsevier Inc.In a complementary report by Bertotti
et al. (2011) using 85 patient-derived
CRC xenografts, ERBB2 was amplified
in 36% of KRAS/NRAS/BRAF/PI3KCA
wild-type tumors that were resistant to
cetuximab. This amplification was greatly
enriched in this population because
ERBB2 was amplified in only 2.7% of
unselected CRCs.
Similar to the mechanism of resistance
reported by Yonesaka et al., resistance
through bypass signaling is seen with
other EGFR-targeted agents. In NSCLC,
amplification of MET was associated
with resistance to the reversible EGFR
tyrosine kinase inhibitor gefitinib via
ERBB3 activation (Engelman et al., 2007).
In HER2 (ERBB2) amplification-positive
breast cancers, resistance to trastuzu-
mab, a humanized antibody directed
against the extracellular domain of
HER2, can be mediated by overexpres-
sion of EGFR and EGFR ligands EGF,
TGF-a, and HB-EGF (Ritter et al., 2007).
These studies and that presented by
Yonesaka et al. illustrate that the effec-
tiveness of monotherapy targeting one
member of the ErbB family may be
compromised by compensatory upregu-
lation or activation of another ERBB
receptor or related receptor tyrosine
kinases (Figure 1).
The identification of ERBB2 as a
mediator of de novo and acquired cetux-
imab resistance suggests that a strategy
of combined targeted therapy in EGFR-
driven malignancies might improve treat-
ment outcomes in a select group of
patients. In preclinical in vitro studies,
combined treatment with cetuximab
and an ERBB2-targeted agent inhibited
growth of cetuximab-resistant cells
(Quesnelle and Grandis, 2011; Yonesaka
et al., 2011). Additionally, treatment
of cetuximab-resistant, KRAS/NRAS/
BRAF/PI3KCA wild-type, ERBB2-ampli-
fied patient-derived xenografts with
combined EGFR and ERBB2-inhibition
resulted in significant tumor regression
(Bertotti et al., 2011). However, early
clinical studies thus far with combined
ERBB receptor inhibition have been
more equivocal. In ERBB2-amplified
breast cancers, combined trastuzumab
and gefitinib treatment was well toler-
ated, but the addition of gefitinib
seemed to provide no obvious benefit
(Arteaga et al., 2008). Whether a strat-
egy of combined EGFR and ERBB2
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Previewsinhibition will prove successful in malig-
nancies amenable to EGFR blockade
remains to be seen and is the subject
of ongoing clinical trials. Consideration
of ERBB2 amplification status with re-
gard to optimal timing of treatment
(i.e., up-front combination or delayed
addition of ERBB2-targeted therapy)
may provide an additional means to
improve outcomes in this patient pop-
ulation. Ultimately, the question remains
as to whether dual EGFR/ERBB2 inhi-
bition will itself be limited by de novo
or induced upregulation of the remaining
ERBB receptors. This answer will be-
come more evident as we begin to ex-
amine the clinical outcome of combined
EGFR and ERBB2-targeted therapy.REFERENCES
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